Experts say the approach could also save millions of pounds by cutting projects or clinical trials that would otherwise fail.

New active ingredients such as antibodies are usually tested individually in laboratory animals. Researchers at UZH have now ...

In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, address ...

Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. Companies specializing in drug ...

Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...

DCT approaches in Japan typically involve partnerships among multiple satellite hospitals. Three main models aim to boost ...

Artificial intelligence continues stirring things up in chemistry. To wit: YC-backed Cambridge, U.K.-based ReactWise is using ...

Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

Clinical research agreements (CRAs) and developing a regulatory strategy—particularly in connection with the Food and Drug Administration ...